Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Month: February 2008
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Galderma Laboratories, LP et al. v. Actavis Mid-Atlantic, L.L.C.4:08-cv-00115; filed February 21, 2008 in the Northern District of Texas Infringement of U.S.…
-
By Baltazar Gomez — Last Thursday, OREXIGEN Therapeutics, Inc. announced that the U.S. Patent and Trademark Office mailed a Notice of Allowance for a patent application directed to the treatment of obesity using zonisamide, either alone or in combination with other drugs. According to OREXIGEN, the allowed application will complement U.S. Patent No.…
-
February 25-26, 2008 – Pharma/Biotech Patent Claim Drafting and Prosecution (American Conference Institute) – New York, NY*** February 25-26, 2008 – Strategic Intellectual Property Planning (American Conference Institute) – Scottsdale, AZ March 12, 2008 – Biotechnology, Chemical & Pharmaceutical Art Group Customer Partnership Meeting (U.S. Patent and Trademark Office) March 30-April 1, 2008 – Advanced…
-
By Kevin E. Noonan — A prominent Israeli commentator has added his voice to the growing chorus of objections to the patent "reform" bill under consideration by the Senate (S. 1145). In an opinion piece published by the Jerusalem Post on Wednesday, Bernard Frieder, a technology specialist with experience consulting on intellectual property…
-
By Donald Zuhn — Last October, we reported on two letters that were sent to the Office of Management and Budget (OMB), each of which criticized the IDS rules package proposed by the U.S. Patent and Trademark Office in July 2006 (see "Changes to Information Disclosure Statement Requirements and Other Related Matters," 71…
-
By Kwame Mensah — Geron Corporation recently announced that it had been granted U.S. Patent No. 7,326,572, entitled "Endoderm cells from human embryonic stem cells." The ‘572 patent covers a method for producing endoderm cells from human embryonic stem cells (hESCs). The production of endoderm cells is a critical step in generating pancreatic…
-
By Christopher P. Singer — In a Federal Register notice published on February 20, 2008, the U.S. Patent and Trademark Office announced proposed changes to the rules regarding submission of biological deposits in patent applications. In particular, the revised rules would require that any deposit of biological material be made before the application…
-
By Kevin E. Noonan — Judge Paul Michel (at right), Chief Judge of the Court of Appeals for the Federal Circuit, recently had the opportunity to speak to a meeting of the Association of Corporate Patent Counsel, one of the preeminent patent law groups in the country and one of the most exclusive…
-
By Jason Derry — Pfizer Inc. has announced that it has an agreement in place to acquire Encysive Pharmaceuticals Inc. for about $195 million. Encysive is a biotechnology company that has a product currently marketed in the European Union, and several other foreign markets, for treating pulmonary arterial hypertension. The product, THELIN (sitaxsentan…
-
By Baltazar Gomez — AstraZeneca PLC announced last Thursday that it was spinning off a portion of its gastrointestinal research operations into new biotech company called Albireo. Albireo will be financed by a syndicate including Nomura Phase4 Ventures, TVM Capital, and Scottish Widows Investment Partnership. AstraZeneca will keep a significant minority stake in…
Patent Docs 